Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DTSD | ISIN: SE0009858152 | Ticker-Symbol: 2B4
Tradegate
27.06.25 | 21:58
25,760 Euro
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
BONESUPPORT HOLDING AB Chart 1 Jahr
5-Tage-Chart
BONESUPPORT HOLDING AB 5-Tage-Chart
RealtimeGeldBriefZeit
25,74025,76028.06.
25,74025,76027.06.
GlobeNewswire (Europe)
370 Leser
Artikel bewerten:
(2)

Bonesupport Holding AB Publishes Year End Report 2024

BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the year end report for the fourth quarter 2024 and full year 2024.

THE GROWTH JOURNEY CONTINUES, STRONG CASH FLOW

"Strong sales growth, record results and groundbreaking clinical outcomes." Emil Billbäck, CEO

OCTOBER - DECEMBER 2024

  • Net sales increased by 49 percent (48 percent at constant exchange rates) and amounted to SEK 257.0 million (172.7).
  • The North America (NA) segment reported a sales growth of 59 percent (58 percent at constant exchange rate).
  • The Europe & Rest of the World (EUROW) segment reported a sales growth of 16 percent (17 percent at constant exchange rates).
  • The gross margin amounted to 92.6 percent (91.8).
  • The operating result before effects from the Group's incentive programs amounted to SEK 78.0 million (11.2). The reported operating result amounted to SEK 64.2 million (-7.7).
  • Earnings per share before dilution were SEK 0.82 (0.16).
  • Earnings per share after dilution were SEK 0.81 (0.16).

JANUARY - DECEMBER 2024

  • Net sales increased by 52 percent (52 percent at constant exchange rates) and amounted to SEK 898.7 million (591.1).
  • The North America (NA) segment reported a sales growth of 62 percent (63 percent at constant exchange rate).
  • The Europe & Rest of the World (EUROW) segment reported a sales growth of 23 percent (22 percent at constant exchange rates).
  • The gross margin amounted to 92.6 percent (91.5)
  • The operating result before effects from the Group's incentive programs amounted to SEK 203.9 million (54.1). The reported operating result amounted to SEK 166.1 million (13.9).
  • Earnings per share before dilution were SEK 2.04 (3.77).
  • Earnings per share after dilution were SEK 2.01 (3.74).
  • Adjusted for deferred tax receivables on tax losses carried forward, which were reported for the first time during the comparison period, the earnings per share before and after dilution were SEK 0.12 during the comparison period.
  • The Board proposed that no dividend be paid for the financial year 2024.


EVENTS DURING THE PERIOD
During the fourth quarter, in accordance with the decision made at the Annual General Meeting in May 2024, the Board of BONESUPPORT decided to utilize the authorization to enter into a share swap agreement with the Company's bank with the purpose of securing the Company's delivery of performance shares to the participants in the Long Term Incentive program that the Annual General Meeting had decided to implement. The swap amounted to SEK 68.7 million.

EVENTS AFTER THE PERIOD
In January 2025, a clinical study including 105 diabetes patients with bone infection in the foot, was reported, that showed that treatment with CERAMENT G or CERAMENT V gave significant advantages compared to standard treatment. The results showed improved infection healing and a dramatic improvement in survival rate to 87.5 percent compared to 44.9 percent in the standard treatment group, over a five year period.

For more information contact:

BONESUPPORT Holding AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

This information is information that BONESUPPORT Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-02-25 08:00 CET.

About BONESUPPORT

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 899 million in 2024. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

© 2025 GlobeNewswire (Europe)
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.